Compare ADM & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADM | ILMN |
|---|---|---|
| Founded | 1902 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Medical Specialities |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.4B | 18.9B |
| IPO Year | N/A | 2000 |
| Metric | ADM | ILMN |
|---|---|---|
| Price | $57.88 | $135.12 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 6 | 16 |
| Target Price | $55.67 | ★ $117.31 |
| AVG Volume (30 Days) | ★ 2.6M | 1.6M |
| Earning Date | 02-03-2026 | 02-05-2026 |
| Dividend Yield | ★ 3.52% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 2.46 | ★ 4.46 |
| Revenue | ★ $83,211,000,000.00 | $4,288,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.44 | $2.24 |
| P/E Ratio | ★ $23.52 | $30.25 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $40.98 | $68.70 |
| 52 Week High | $65.00 | $153.06 |
| Indicator | ADM | ILMN |
|---|---|---|
| Relative Strength Index (RSI) | 43.38 | 61.86 |
| Support Level | $57.29 | $132.93 |
| Resistance Level | $58.10 | $138.80 |
| Average True Range (ATR) | 1.13 | 3.96 |
| MACD | -0.12 | -0.42 |
| Stochastic Oscillator | 19.30 | 70.39 |
Archer-Daniels-Midland is a major processor of oilseeds, corn, wheat, and other agricultural commodities. The company is also one of the largest grain merchandisers through its extensive network of logistical assets to store and transport crops around the globe. ADM also runs a nutrition business that focuses on both human and animal ingredients and is a large producer of corn-based sweeteners, starches, and ethanol.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.